GlassScriptPhysician profile
Anne Fisher
NPI 1609161660
$816.77
in general payments reported to CMS, 2019-2025
16 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.25 · 2022: $44.09 · 2023: $396 · 2024: $152 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $239.18 | 2021-2024 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Ha+ Nerve Protector |
| Abbott Laboratories | $109.08 | 2024-2025 | Freestyle Libre 3 |
| Corium, LLC | $107.83 | 2023 | Azstarys |
| Integra Lifesciences Corporation | $75.09 | 2023-2024 | Tenoglide, Inspira Air, Acclarent Aera |
| Lilly USA, LLC | $53.02 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $38.03 | 2024-2025 | Rybelsus, Ozempic |
| Baxter Healthcare | $30.56 | 2025 | Tisseel |
| Genzyme Corporation | $28.79 | 2025 | |
| Idorsia Pharmaceuticals US INC | $21.28 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $18.77 | 2021 | |
| Polynovo North America LLC | $17.96 | 2022 | |
| Madrigal Pharmaceuticals | $16.81 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $15.55 | 2023 | Farxiga |
| Djo, LLC | $15.51 | 2023 | Aircast, Cmf, Procare |
| Pfizer INC. | $14.87 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.44 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.